| Dr Abiy Mulugeta Abebe, MD | |
|
1227 E Rusholme St, Davenport, IA 52803-2459 | |
| (563) 421-1000 | |
| Not Available |
| Full Name | Dr Abiy Mulugeta Abebe |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 24 Years |
| Location | 1227 E Rusholme St, Davenport, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154855104 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 47181 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holy Cross Hospital | Silver spring, MD | Hospital |
| Baptist Health Floyd | New albany, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Usacs Integrated Acute Care Services Of Maryland Llc | 4486900172 | 218 |
| New Albany Hospitalist Group, Llc | 4880041409 | 65 |
News Archive
People who have been exposed to chemical warfare agents (CWAs) feel uncertain, decades after the exposure, about their survival and ability to build a family, a University of Gothenburg study shows. Women are more severely affected than men.
A new gene mutation which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children has been discovered for the first time by University of Leeds experts.
PPD, Inc. today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company's ability to deliver secure, quality reporting and data analysis to meet client timelines.
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 7 days ago
| Entity Name | Usacs Integrated Acute Care Services Of Maryland Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922598929 PECOS PAC ID: 4486900172 Enrollment ID: O20190604001354 |
News Archive
People who have been exposed to chemical warfare agents (CWAs) feel uncertain, decades after the exposure, about their survival and ability to build a family, a University of Gothenburg study shows. Women are more severely affected than men.
A new gene mutation which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children has been discovered for the first time by University of Leeds experts.
PPD, Inc. today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company's ability to deliver secure, quality reporting and data analysis to meet client timelines.
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Abiy Mulugeta Abebe, MD 1227 E Rusholme St, Davenport, IA 52803-2459 Ph: (563) 421-1000 | Dr Abiy Mulugeta Abebe, MD 1227 E Rusholme St, Davenport, IA 52803-2459 Ph: (563) 421-1000 |
News Archive
People who have been exposed to chemical warfare agents (CWAs) feel uncertain, decades after the exposure, about their survival and ability to build a family, a University of Gothenburg study shows. Women are more severely affected than men.
A new gene mutation which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children has been discovered for the first time by University of Leeds experts.
PPD, Inc. today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data. The biostatistics technology infrastructure (BTI) is a centralized computing platform that enhances the company's ability to deliver secure, quality reporting and data analysis to meet client timelines.
Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.
Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for a new, smaller version of the CYPHER® Sirolimus-eluting Coronary Stent, the world's most studied drug-eluting stent that has been used to treat nearly 4 million people worldwide. The new 2.25 mm CYPHER® Stent is indicated for treatment of coronary blockages in small vessels, an often difficult-to-treat situation.
› Verified 7 days ago
Dr. Humphrey Wong, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1801 E 54th St, Ste 100, Davenport, IA 52807 Phone: 563-323-1229 Fax: 563-323-8240 | |
Mouhamed Walid Al Sheikha, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2162 W Kimberly Rd, Davenport, IA 52806 Phone: 563-391-1024 Fax: 563-391-1024 | |
Louis M Katz, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1351 W Central Park Ave, Davenport, IA 52804 Phone: 563-421-4244 Fax: 563-421-4285 | |
Catherine L Weideman, MD Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 1351 W Central Park Ave, Ste 350, Davenport, IA 52804 Phone: 563-421-4620 Fax: 563-421-4625 | |
Dr. Eric J Dippel, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3385 Dexter Ct Ste 100, Davenport, IA 52807 Phone: 563-324-3818 Fax: 563-326-4280 | |
Sami Faruqui, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1970 E 53rd St, Davenport, IA 52807 Phone: 563-359-3949 Fax: 563-355-1159 | |
Dr. Akshay Kantilal Mahadevia, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 3385 Dexter Ct Ste 102, Davenport, IA 52807 Phone: 563-323-1352 Fax: 855-274-1654 |